In Pennsylvania, this alleged illegal activity forced consumers and government agencies to pay much higher prices for the brand-name, anti-anxiety drug, ... It appears Bristol-Myers Squibb attempted to manipulate federal drug regulations to extend the patent and continue its monopoly on the product.
